跳至主要内容
临床试验/CTRI/2021/06/033998
CTRI/2021/06/033998已完成未知

An Open Label, Single-Arm, Multicentre, Clinical Study to Evaluate Efficacy and Safety of Anti-Dandruff Shampoo (HAMC-081905) in subjects with dandruff

The Himalaya Drug Company0 个研究点目标入组 99 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
99

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Age: 18 to 60 years (both inclusive) at the time of consent.
  • 2.Sex: Healthy male or non-pregnant/non-lactating female.
  • 3.Female subjects of childbearing potential must have a negative urine pregnancy test performed on screening visit and Enrolment.
  • 4.Subjects generally in good health and willing to give written informed consent and willing to follow study procedure.
  • 5.Subjects with dandruff determined by ASFS score 24 to 48 with itching and flaking.
  • 6.Subjects with visible flakes.
  • 7.Subjects willing to refrain from using other products on the scalp other than those provided, including other shampoos/conditioners, scalp and hair treatment and oils/ products that has anti-dandruff action during the study period.
  • 8.Subjects completing the conditioning phase.
  • 9.Subjects willing to use test product throughout the study period.
  • 10.Subjects must be able to understand and provide written informed consent to participate in the study.
  • 11.Subjects should be willing and able to follow the study protocol to participate in the study.

排除标准

  • 1)History of any dermatological conditions of the scalp (other than dandruff or seborrheic dermatitis) that would interfere with the diagnosis or assessment (e.g. psoriasis, eczema, atopic dermatitis, or other skin/scalp infections).
  • 2)Subjects with excessive erythema, crusting or a significant number of pustules/papules on the scalp.
  • 3)History of skin cancer or treatment for any type of cancer within the last 2 years.
  • 4)History of prior use of antidandruff treatment on scalp within past 1 month.
  • 5)Participation in a similar clinical study within the previous 90 Days.
  • 6)Subjects with a history or present condition of an allergic response to dandruff shampoos or any cosmetic products or component present in the test product.
  • 7)Any other condition which could warrant exclusion from the study, as per the Dermatologistââ?¬•s/investigatorââ?¬•s discretion

研究者

相似试验

已完成
不适用
Anti-Dandruff Shampoo Testing on healthy male and females adult subjects.
CTRI/2021/06/034226The Himalaya Drug Company102
进行中(未招募)
不适用
A study comparing the use of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects with Rheumatoid Arthritis
EUCTR2014-004887-39-PLSamsung Bioepis Co., Ltd
尚未招募
4 期
A Clinical Investigation study in Indian population to evaluate the Safety and Efficacy of Los DelineTM for contour & volume correction of Human Soft Tissues.
CTRI/2023/09/057513JCP International Private Limited
进行中(未招募)
1 期
Clinical trial in patients with advanced breast cancer (hormone receptor-positive, HER2-negative) receiving palbociclib and standard therapy with an aromatase inhibitor or fulvestrant after prior endocrine therapy.The study population includes postmenopausal patients with advanced (locally recurrent, inoperable and/or metastatic), HR+, HER2- breast cancer. For peri-/premenopausal patients, endocrine therapy has to be combines with a luteinizing hormone-releasinghormone (LRHR) agonist.MedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864MedDRA version: 23.0Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 100000004864
EUCTR2015-001603-32-DEiOMEDICO AG360
Unknown
3 期
Clinical trial to determine the efficacy and tolerability of oral iron preparations in iron deficiency aneamia in pregnancy
CTRI/2021/07/035277GC Chemie Pharmie Ltd4